Physician profile
Hillary Elizabeth Lockemer
NPI 1457512493
$17,652.08
in general payments reported to CMS, 2019-2025
23 companies · $17K in 2025
The $17K reported for 2025 was more than what 92% of Pediatric Endocrinology providers received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2020: $43.17 · 2022: $85.02 · 2023: $242 · 2024: $237 · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,390 · Food and Beverage: $1,274 · Travel and Lodging: $846.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,740.70 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,390.00 |
| Food and Beverage | $1,274.43 |
| Travel and Lodging | $846.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $13,073.86 | 2025 | |
| Sanofi-Aventis U.S. LLC | $3,554.07 | 2023-2025 | |
| Sequel Med Tech, LLC | $189.86 | 2024-2025 | Twiist |
| Novo Nordisk INC | $157.81 | 2019-2023 | Norditropin |
| Ascendis Pharma Endocrinology INC | $79.96 | 2022-2023 | |
| Arbor Pharmaceuticals, INC. | $61.71 | 2019-2020 | |
| Tolmar, INC. | $59.12 | 2023-2024 | |
| Abbvie INC. | $57.50 | 2020-2024 | |
| Dexcom, INC. | $56.23 | 2023 | Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $52.46 | 2019 | |
| Medtronic, INC. | $43.77 | 2023 | Minimed 780g |
| Xeris Pharmaceuticals, INC. | $42.66 | 2022-2024 | Gvoke Hypopen |
| Beta Bionics, INC. | $41.37 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Pfizer INC. | $33.56 | 2019-2023 | |
| Endo USA, INC. | $24.14 | 2024 | Supprelin |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $22.48 | 2024 | Triptodur |
| Ibsa Pharma INC. | $22.00 | 2023 | Tirosint, Licart |
| Kyowa Kirin, INC. | $21.97 | 2024 | Crysvita |
| Abbott Laboratories | $20.08 | 2024 | Freestyle Libre 3 |
| Companion Medical, INC. | $14.31 | 2020 | |
| Lilly USA, LLC | $12.33 | 2019 | |
| Insulet Corporation | $10.83 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hillary Lockemer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.